Scintigraphic biomarkers for colonic dysmotility

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Scintigraphic colonic transit measurement has emerged as a unique disease-related biomarker pertinent to drug development and personalized therapy. This surrogate offers reproducible and accurate performance across a spectrum of common colonic motility disorders, linking colonic transit measurements to biological processes and clinical end points. The pathobiologic validity, prognostic utility, performance characteristics, evidence-based linkage of therapeutic intervention with outcome, applicability across distinct pharmacodynamic profiles, and potential for individualizing patient management are all attributes of this gastrointestinal imaging paradigm. The cumulative evidence suggests that the integration of colonic transit measurement as a biomarker would accelerate the development and regulatory approval of therapeutic agents for the treatment of colonic dysmotility.

Original languageEnglish (US)
Pages (from-to)748-753
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume87
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

Biomarkers
Biological Phenomena
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Scintigraphic biomarkers for colonic dysmotility. / Camilleri, Michael.

In: Clinical Pharmacology and Therapeutics, Vol. 87, No. 6, 06.2010, p. 748-753.

Research output: Contribution to journalArticle

@article{6dcbf3f00ba24fee807366ef924152f1,
title = "Scintigraphic biomarkers for colonic dysmotility",
abstract = "Scintigraphic colonic transit measurement has emerged as a unique disease-related biomarker pertinent to drug development and personalized therapy. This surrogate offers reproducible and accurate performance across a spectrum of common colonic motility disorders, linking colonic transit measurements to biological processes and clinical end points. The pathobiologic validity, prognostic utility, performance characteristics, evidence-based linkage of therapeutic intervention with outcome, applicability across distinct pharmacodynamic profiles, and potential for individualizing patient management are all attributes of this gastrointestinal imaging paradigm. The cumulative evidence suggests that the integration of colonic transit measurement as a biomarker would accelerate the development and regulatory approval of therapeutic agents for the treatment of colonic dysmotility.",
author = "Michael Camilleri",
year = "2010",
month = "6",
doi = "10.1038/clpt.2010.23",
language = "English (US)",
volume = "87",
pages = "748--753",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Scintigraphic biomarkers for colonic dysmotility

AU - Camilleri, Michael

PY - 2010/6

Y1 - 2010/6

N2 - Scintigraphic colonic transit measurement has emerged as a unique disease-related biomarker pertinent to drug development and personalized therapy. This surrogate offers reproducible and accurate performance across a spectrum of common colonic motility disorders, linking colonic transit measurements to biological processes and clinical end points. The pathobiologic validity, prognostic utility, performance characteristics, evidence-based linkage of therapeutic intervention with outcome, applicability across distinct pharmacodynamic profiles, and potential for individualizing patient management are all attributes of this gastrointestinal imaging paradigm. The cumulative evidence suggests that the integration of colonic transit measurement as a biomarker would accelerate the development and regulatory approval of therapeutic agents for the treatment of colonic dysmotility.

AB - Scintigraphic colonic transit measurement has emerged as a unique disease-related biomarker pertinent to drug development and personalized therapy. This surrogate offers reproducible and accurate performance across a spectrum of common colonic motility disorders, linking colonic transit measurements to biological processes and clinical end points. The pathobiologic validity, prognostic utility, performance characteristics, evidence-based linkage of therapeutic intervention with outcome, applicability across distinct pharmacodynamic profiles, and potential for individualizing patient management are all attributes of this gastrointestinal imaging paradigm. The cumulative evidence suggests that the integration of colonic transit measurement as a biomarker would accelerate the development and regulatory approval of therapeutic agents for the treatment of colonic dysmotility.

UR - http://www.scopus.com/inward/record.url?scp=77952581741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952581741&partnerID=8YFLogxK

U2 - 10.1038/clpt.2010.23

DO - 10.1038/clpt.2010.23

M3 - Article

C2 - 20410880

AN - SCOPUS:77952581741

VL - 87

SP - 748

EP - 753

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -